Literature DB >> 20394766

The relationship between macular pigment and visual performance.

James Loughman1, Mukunda C Akkali, Stephen Beatty, Grainne Scanlon, Peter A Davison, Veronica O'Dwyer, Tom Cantwell, Philip Major, Jim Stack, John M Nolan.   

Abstract

This study was designed to assess whether macular pigment optical density (MPOD) is associated with visual performance. One hundred and forty-two young healthy subjects were recruited. Macular pigment optical density and visual performance were assessed by psychophysical tests including best corrected visual acuity (BCVA), mesopic and photopic contrast sensitivity, glare sensitivity, photostress recovery time (PRT). Measures of central visual function, including BCVA and contrast sensitivity, were positively associated with MPOD (p<0.05, for all). Photostress recovery and glare sensitivity were unrelated to MPOD (p>0.05). A longitudinal, placebo-controlled and randomized supplementation trial will be required to ascertain whether augmentation of MPOD can influence visual performance. 2010 Elsevier Ltd. All rights reserved.

Mesh:

Substances:

Year:  2010        PMID: 20394766     DOI: 10.1016/j.visres.2010.04.009

Source DB:  PubMed          Journal:  Vision Res        ISSN: 0042-6989            Impact factor:   1.886


  24 in total

1.  The use of heterochromatic flicker photometry to determine macular pigment optical density in a healthy Australian population.

Authors:  Robin G Abell; Alex W Hewitt; Marko Andric; Penelope L Allen; Nitin Verma
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-01-05       Impact factor: 3.117

2.  The macular pigment optical density spatial profile and increasing age.

Authors:  Raymond O Beirne
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-10-01       Impact factor: 3.117

3.  Macular pigment spatial distribution effects on glare disability.

Authors:  Christopher M Putnam; Carl J Bassi
Journal:  J Optom       Date:  2015-02-16

4.  The association between dark adaptation and macular pigment optical density in healthy subjects.

Authors:  Laura Patryas; Neil R A Parry; Dave Carden; Tariq Aslam; Ian J Murray
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-01-12       Impact factor: 3.117

5.  Evaluation of the association between macular damage and disability glare in patients with advanced glaucoma.

Authors:  Yun Hsia; Tsing-Hong Wang; Jehn-Yu Huang; Chien-Chia Su
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-02-22       Impact factor: 3.535

6.  Rod-Mediated Dark Adaptation and Macular Pigment Optical Density in Older Adults with Normal Maculas.

Authors:  Anna V Zarubina; Carrie E Huisingh; Mark E Clark; Kenneth R Sloan; Gerald McGwin; Jason N Crosson; Christine A Curcio; Cynthia Owsley
Journal:  Curr Eye Res       Date:  2018-05-01       Impact factor: 2.424

Review 7.  Lutein, zeaxanthin, and meso-zeaxanthin: The basic and clinical science underlying carotenoid-based nutritional interventions against ocular disease.

Authors:  Paul S Bernstein; Binxing Li; Preejith P Vachali; Aruna Gorusupudi; Rajalekshmy Shyam; Bradley S Henriksen; John M Nolan
Journal:  Prog Retin Eye Res       Date:  2015-11-02       Impact factor: 21.198

8.  Nutrient reference values for bioactives: new approaches needed? A conference report.

Authors:  Hans Konrad Biesalski; John W Erdman; John Hathcock; Kathleen Ellwood; Stephen Beatty; Elizabeth Johnson; Roberto Marchioli; Lotte Lauritzen; Harry B Rice; Andrew Shao; James C Griffiths
Journal:  Eur J Nutr       Date:  2013-04       Impact factor: 5.614

9.  Improvement or Worsening of Human Contrast Sensitivity Due to Blue Light Attenuation at 450 nm.

Authors:  Silvia Tavazzi; Federica Cozza; Gabriele Nigrotti; Chiara Braga; Natalia Vlasak; Silvano Larcher; Fabrizio Zeri
Journal:  Clin Optom (Auckl)       Date:  2020-04-01

10.  Visual performance in patients with neovascular age-related macular degeneration undergoing treatment with intravitreal ranibizumab.

Authors:  Sarah Sabour-Pickett; James Loughman; John M Nolan; Jim Stack; Konrad Pesudovs; Katherine A Meagher; Stephen Beatty
Journal:  J Ophthalmol       Date:  2013-02-21       Impact factor: 1.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.